BACKGROUND: The relationship between @entity4854 and arterial recanalization following intravenous recombinant @entity1456 treatment in acute @entity385 is not well understood. AIM: We aimed to evaluate the effects of @entity4854 in thrombolysed @entity385 @entity1 on recanalization rate and clinical outcome. METHODS: We studied 348 (231 subjects from the CLOTBUST databank and 117 subjects from the CLOTBUST trial phase II) with documented intracranial @entity432 treated with intravenous recombinant @entity1456 . Serum @entity413 was determined at baseline before intravenous recombinant @entity1456 administration. @entity4854 was defined as a @entity413 level >= 140   mg/dl (7  7   mmol/l). Transcranial Doppler findings were interpreted using the thrombolysis in @entity2806 flow grading system as persistent @entity432 , re-occlusion or complete recanalization. Poor clinical outcome was defined by modified Rankin score   >   2 at three-months. RESULTS: At baseline, 138 @entity1 (37  4%) were @entity1602 and 210 @entity1 (56  9%) normoglycemic. Baseline characteristics based on @entity413   >=    140 (7  7   mmol/l) or less 140: age (70  0        12  4 vs. 67  3        14  1, P   =   0  065), baseline National Institutes of Health @entity64 Scale (17  0        5  5 vs. 15  8        5  5, P   =   0  054), time to recombinant @entity1456 (141  4        69  1 vs. 145  3        48  4 mins, P   =   0  56), and history of @entity6 [60/138 (43  5%) vs. 22/210 (10  5%), P   <   0  001]). @entity1 with @entity4854 have a higher rate of persisting occlusion [72/138 (52  2%) vs. 66/210 (31  4%)] and less rate of complete recanalization [34/138 (24  6%) vs. 82/210 (39%), P   <   0  001]. Median time to recanalization in @entity1 with severe @entity4854 ( @entity413   >=    200) (11   mmol/l) and @entity413 <200 was 163        79 and 131        90   mins, respectively (P   =   0  045). Sixteen @entity1 (11  6%) in the @entity1602 group and 12 (5  7%) in the normoglycemic group had symptomatic @entity1779 (P   =   0  049). Seventy-eight @entity1 (69%) in the @entity4854 group and 72 @entity1 (41  6%) in the normoglycemic group had poor clinical outcome (three-month modified Rankin score   >   2) (P    <=   0  001). After adjusting for @entity64 risk factors, @entity1 with @entity4854 were more likely to have poor clinical outcome (three-month modified Rankin score   >   2) (adjusted odds ratio   =   2  22, 95% confidence interval: 1  2-4  11, P   =   0  011) and low complete recanalization rate (adjusted odds ratio: 0  5, confidence interval: 0  3-0  92, P   =   0  025) with trend of increase risk of symptomatic @entity1779 (adjusted odds ratio: 2  07, confidence interval:0  8-5  1, P   =   0  114). There was no association between baseline @entity413 as a continuous variable and poor clinical outcome, but there was with the complete recanalization's rate. CONCLUSION: @entity4854 is associated with low rate of complete recanalization and poor clinical outcome in intravenous recombinant @entity1456 -treated @entity1 . Further studies are needed to evaluate whether lowering @entity4854 is beneficial in the management of @entity64 @entity1 .

The correlation between admission blood @entity413 and intravenous rt-PA-induced arterial recanalization in acute XXXX : a multi-centre TCD study.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'Stroke', 'acute stroke'] @entity2806 :: ('MESH:D002545', 'Disease') :: ['brain ischemia'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity1456 :: ('100128998', 'Gene') :: ['tissue-plasminogen activator'] @entity1602 :: ('MESH:D006944', 'Disease') :: ['hyperglycemic'] @entity1779 :: ('MESH:D002543', 'Disease') :: ['intracerebral hemorrhage'] @entity432 :: ('MESH:D001157', 'Disease') :: ['artery occlusion', 'arterial occlusion'] @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia', 'Hyperglycemia'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity385 :: (MESH:D002544,Disease) :: ['ischemic stroke']
